Association between polymorphisms in cell cycle genes and advanced prostate carcinoma

Single nucleotide polymorphisms (SNPs) have been associated with a variety of malignancies including prostate carcinoma (PCa). Since a high percentage of PCa patients have low risk disease, of particular interest is not whether SNPs are associated with localized PCa, but whether they are associated with aggressive, potentially lethal disease. Herein, we explored the role of SNPs in cell cycle genes to determine if they were associated with advanced PCa.

[1]  T. Dörk,et al.  Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. , 2007, Cancer research.

[2]  Adam S. Kibel,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007 .

[3]  A. Levine,et al.  MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. , 2006, Cancer research.

[4]  Wen Tan,et al.  Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer , 2006, Human mutation.

[5]  W. Tan,et al.  The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. , 2005, Cancer research.

[6]  T. Hudson,et al.  Functional promoter SNPs in cell cycle checkpoint genes. , 2005, Human molecular genetics.

[7]  M. Kattan,et al.  Testosterone as a predictor of pathological stage in clinically localized prostate cancer. , 2005, The Journal of urology.

[8]  J. Yokota,et al.  Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk , 2005, International journal of cancer.

[9]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[10]  E. Wilson,et al.  Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression. , 2005, Molecular endocrinology.

[11]  X. Shu,et al.  Association of cyclin D1 genotype with breast cancer risk and survival. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  Ming-Tsang Wu,et al.  p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  Jianfeng Xu,et al.  A Polymorphism in the CDKN1B Gene Is Associated with Increased Risk of Hereditary Prostate Cancer , 2004, Cancer Research.

[14]  D. Pim,et al.  p53 polymorphic variants at codon 72 exert different effects on cell cycle progression , 2004, International journal of cancer.

[15]  H. Yamanaka,et al.  Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. , 2003, Anticancer research.

[16]  C. Franceschi,et al.  Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  K. Matsuo,et al.  Association ofp53 codon arg72pro andp73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of japanese breast cancer , 2003, Breast cancer.

[18]  M. Devoto,et al.  CARD15 genotyping in inflammatory bowel disease patients by multiplex pyrosequencing. , 2003, Clinical chemistry.

[19]  P. Walsh,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.

[20]  Kazuto Ito,et al.  A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. , 2003, Journal of biomedical science.

[21]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[22]  A. Kibel,et al.  CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. , 2003, Cancer research.

[23]  E. Liu,et al.  Genetic background is an important determinant of metastatic potential , 2003, Nature Genetics.

[24]  O. Akilov,et al.  Association between human demodicosis and HLA class I , 2003, Clinical and experimental dermatology.

[25]  Li Zhao,et al.  Cyclin D1 Is a Ligand-independent Co-repressor for Thyroid Hormone Receptors* , 2002, The Journal of Biological Chemistry.

[26]  T. Habuchi,et al.  Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. , 2002, Carcinogenesis.

[27]  K. Broman,et al.  Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. , 2001, Cancer research.

[28]  T. Beer,et al.  Association of codon 72 polymorphism of p53 with lower prostate cancer risk , 2001, The Prostate.

[29]  M. Spitz,et al.  Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. , 2001, Carcinogenesis.

[30]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[31]  A. Kibel,et al.  G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. , 2000, Urology.

[32]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[33]  H. Kamada,et al.  Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner , 1998, Oncogene.

[34]  M. Becich,et al.  Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin‐dependent kinase inhibitor gene , 1997, Cancer.

[35]  Stephen J. Elledge,et al.  Cell Cycle Checkpoints: Preventing an Identity Crisis , 1996, Science.

[36]  P. Humphrey,et al.  Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. , 1996, The Journal of urology.

[37]  N Thatcher,et al.  Alternate splicing produces a novel cyclin D1 transcript. , 1995, Oncogene.

[38]  T. Stamey,et al.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. , 1994, The Journal of urology.

[39]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[40]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[41]  L. J. Veer,et al.  The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes , 2007, European Journal of Human Genetics.

[42]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[43]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[44]  T. Habuchi,et al.  Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism , 2003, International journal of cancer.

[45]  L. Marchand,et al.  Association of the Cyclin D 1 A 870 G Polymorphism With Advanced Colorectal Cancer , 2003 .

[46]  P. Sham.  Statistics in human genetics , 1997 .

[47]  J. Ott,et al.  A chi‐square test to distinguish allelic association from other causes of phenotypic association between two loci , 1985, Genetic epidemiology.